Vimta Labs — Q1 FY26 earnings call

Call held 21 Jul 2025

Management summary

Vimta Labs delivered a robust Q1 FY26, achieving its highest-ever quarterly revenue of INR993 million, a 31.4% YoY increase, driven by strong performance in pharmaceutical testing and research. Profitability metrics also saw significant gains, with EBITDA and PAT growing over 33% YoY. The company successfully navigated a US FDA inspection and announced a 1:1 bonus issue, reflecting strong operational and financial health. However, management foresees a temporary 1-2% margin compression due to new facility costs and rising HR expenses, and noted a flat domestic revenue trend.

Highlights

  • Revenue reached an all-time high of INR993 million, demonstrating a substantial 31.4% year-on-year growth.

  • EBITDA increased by 33.1% year-on-year to INR354 million, maintaining strong margins at 35.7%.

  • Profit after tax (PAT) grew by 35.9% year-on-year to INR189 million, with PAT margins at 19%.

  • Successfully completed an unannounced US FDA GCP inspection with zero Form 483 observations, highlighting quality and scientific precision.

  • The Board approved a 1:1 bonus issue, showcasing strong financial position and confidence in future growth.

Concerns

  • Management anticipates a potential 1-2% reduction in EBITDA margins in the coming quarters due to new facility maintenance, lab redesigning, and increasing human resource costs, before stabilization.

  • Domestic revenue has remained flat or slightly degrown, which management attributes to market maturity rather than decline.

  • Acknowledged risk of US tariffs impacting exports, though no direct impact has been observed so far.

Key financials

  1. Revenue 993 Mn +31.4%YoY
  2. EBITDA 354 Mn +33.1%YoY
  3. EBITDA Margin 35.7%
  4. PAT 189 Mn +35.9%YoY
  5. PAT Margin 19%
  6. Cash and Cash Equivalents 379.3 Mn

What they filed

Q1 FY27: revenue up 11.2%, net profit up 10.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue85 90 94 98 102 +20%99 +10%109 +16%109 +11%
EBITDA30 33 33 34 34 +13%34 +3%39 +18%37 +9%
Net profit15 22 18 19 20 +33%18 −18%21 +17%21 +11%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex ₹100 Cr
    • Biologics contract research and development services setup ₹30 Cr
    • New/replacement equipment and capacity expansion across business units
    • Digitization and automation of processes
    Okay. Last year, majority of the capex was spent on the new facility that we have built. So it's not INR20 crores. I think it's upward of INR60 crores, Siva can confirm. And the remainder was for equipment. And equipment, it's a routine spend for us, whether it is to add new equipment or to replace existing old equipment. Typically, what we use is depreciation that is available for us. So this is continuous. Again, this year, we have a large capex outlay, again, to complete the final payments for that new building that we have done. And also about INR30 crores is planned for the biologics contract, research and development services setup. And the remainder is for expanding our capacities across our business units. And also, like I was mentioning a little earlier, we are investing quite a bit on digitizing and automating our processes. So some expenditure is expected even in that direction.
  • Debt Debt disclosed
    On the balance sheet side, we continue to have a net debt-free balance sheet with cash and cash equivalents of INR379.3 million.
  • Liquidity Cash ₹379.3 Mn
    On the balance sheet side, we continue to have a net debt-free balance sheet with cash and cash equivalents of INR379.3 million.

Guidance & targets

Revenue

  • Exit quarterly revenue Revenue · FY26 · Medium confidence INR120-125 crores
    And coming to whether we are on track with that INR120 crores to INR125 crores per quarter, yes, that's where our efforts are really being put, and we are striving very hard to reach that goal.

    — Harita Vasireddi

  • Revenue Growth (existing business) Revenue · Next few years · Medium confidence 15-20% CAGR
    I think we have been growing at a healthy CAGR during the last 5 years, and we hope to continue that. We want to give it a push because we have a goal to achieve this year. But I think year-on-year, if you are growing at that rate of 15%, anywhere between 15% to 20%, then you're growing at a speed that is double of the industry. So that's a good growth rate to target.

    — Harita Vasireddi

Profitability

  • EBITDA Margin Profitability · Coming quarters or couple of years · Low confidence Reduce by 1-2%
    Margins might reduce by 1% or 2%, and this could happen in the coming quarters or the coming couple of years. Very difficult to predict, okay?

    — Harita Vasireddi

Capacity

  • Biologics commercialization Capacity · Q1 FY27 · High confidence Commercializing from Q1 FY27
    I would like to share that currently, equipment procurement is in progress and in line with the timelines of commercializing the same from Q1 FY 2027.

    — Harita Vasireddi

  • New facility capacity utilization Capacity · Next 5 years · High confidence Manage growth for next half a decade (5 years)
    you have enough space now for the to manage the growth for the next half a decade, which means for the next 5 years. Is that right? Yes.

    — Harita Vasireddi

What to watch in Q2 FY26

Biologics commercialization timeline

Q1 FY27
Current Equipment procurement in progress
Target On track for commercialization from Q1 FY27

Why it matters

This is a new, high-growth area for Vimta, and its successful commercialization is key to future revenue streams.

I would like to share that currently, equipment procurement is in progress and in line with the timelines of commercializing the same from Q1 FY 2027.

Risks & concerns

  • Impact of US tariffs on exports

    medium

    Potential for tariffs to impact exports, though no direct impact has been observed so far. Vimta's strength is catering to high-quality requirements of developed markets.

    Analyst acknowledged

  • Margin compression due to new facility costs and rising HR expenses

    medium

    New facility maintenance, lab redesigning, and increasing human resource costs may lead to a 1-2% margin reduction in the coming quarters before stabilization.

    Management acknowledged

  • Strain on qualified manpower

    low

    The proliferation of more laboratories in the market is creating a strain on qualified manpower.

    Management acknowledged

Q&A highlights

6 direct, 1 evasive
Biologics segment entry, competition, and cross-selling strategy Direct
The idea behind pursuing a contract research and development of large molecules is to get the benefit of all these services and add also formulation development, making it a complete end-to-end package for our customers. So that's a huge advantage that Vimta provides because although there is competition in the market for contract development and research, not everybody is having clinical research and analytical research and analytical as a complete package. So there, Vimta will stand out to be quite unique.

Clarifies the strategic rationale and competitive differentiation for Vimta's entry into biologics, emphasizing the end-to-end service package.

Asked by Pujan Shah

Growth outlook for electrical and electronic testing Direct
This is a sunrise industry. It's a newer industry, especially the testing services for electronics. I think the major push for these services will come from defense and telecom in the next couple of years... And Hyderabad is actually quite a big hub for such OEMs. And this is a 3-year-old business for us. It is growing organically. But I think the future is bright because even the regulations are just beginning to be developed.

Provides insight into a newer, high-potential segment, its drivers (defense, telecom, regulations), and geographic advantage.

Asked by Pujan Shah

Clinical trials progress and pipeline conversion Direct
The pipeline, like I mentioned, is quite encouraging. During the last quarter, we have received a decent number of enquiries, and out of which a couple of them are in the final stages of getting converted. The rest also looks promising. Like I was telling in some of my previous calls, this is a new activity for us. So initially, it will take us some time to build the clientele. But happy to share that this is progressing well.

Gives an update on the nascent but promising clinical trials business, indicating positive traction and potential for future growth.

Asked by Umesh Matkar

Impact of US biotech funding slowdown and potential tariffs Partial
Percentages, I don't have that calculation with me here, but we are not observing any slowdown in -- from that segment of the industry, none... Definitely, there's a risk. If, I think, the tariffs and all are increased, then the exports might get impacted... But so far, we have not seen any impact of such possibilities.

Addresses potential macro risks (funding, tariffs) from the US market, with management acknowledging the risk but stating no current impact on their business.

Asked by Kanv Garg

Capex breakdown and revenue contribution from new equipment Direct
Last year, majority of the capex was spent on the new facility that we have built... this year, we have a large capex outlay, again, to complete the final payments for that new building that we have done. And also about INR30 crores is planned for the biologics contract, research and development services setup. And the remainder is for expanding our capacities across our business units.

Clarifies the significant capex investments made in the new facility and planned for biologics, indicating future growth drivers and capacity.

Asked by Ajay Surya

Capacity utilization and maximum revenue potential from new facilities Evasive
What we have done is we have created infrastructure for future growth that will serve our growth for at least the next half a decade or so... Coming to the revenue potential, again, very difficult for us to estimate, but we think this will be good for the next half a decade of growth... Very difficult to put a number on that. Give me a year or so, maybe I'll be able to predict that more accurately.

Analyst pushes for quantification of revenue potential from new capacity, but management remains qualitative, highlighting the long-term nature of the investment without specific numbers.

Asked by Ashutosh Garud

Sustainability of EBITDA margins given new investments and costs Direct
The margins, what we have are excellent right now. But like I said, there's a lot of capacity that we have added, and with that comes a lot of maintenance also. And we are also redesigning some of our labs. So there's a cost to that, which we will spend on. So in that aspect, we can expect the margins to come down a few basis points before, it is stabilized.

Management explicitly guides for a temporary dip in margins due to operational costs associated with new capacity, which is a key concern for investors.

Asked by Ashutosh Garud

Domestic revenue trend (flat/degrowing) despite industry growth Direct
I think that -- a different way of looking at this..... there is no degrowth in the domestic business. It has not grown at the pace at which the export business has obviously grown. That's because our business in India has reached a mature level. We are working with a lot of customers here, whereas there's a lot more market to address when you go overseas. So I don't think we should look at this with any negative connotation.

Addresses a potential red flag regarding domestic market performance, with management explaining it as a mature market with less growth potential compared to exports, rather than a decline.

Asked by Ajay Surya

3 min read 7 chapters

Detailed narrative

Q1 FY26 Financial Performance Highlights

Vimta Labs achieved its highest-ever quarterly revenue of INR993 million in Q1 FY26, marking a substantial 31.4% year-on-year growth. This strong top-line performance translated into robust profitability, with EBITDA increasing by 33.1% to INR354 million, maintaining a healthy margin of 35.7%. Profit after tax (PAT) also saw a significant jump of 35.9% year-on-year, reaching INR189 million, with PAT margins at 19%. The company maintains a net debt-free balance sheet with INR379.3 million in cash and cash equivalents.

Pharmaceutical and Food Testing Business Update

Pharmaceutical testing and research services remain a major revenue contributor, meeting management expectations. The company successfully completed an unannounced US FDA GCP inspection with no Form 483 observations and received cGMP compliance from ANSM EMA. In the food testing segment, consistent business growth is observed, supported by the establishment of a new food lab in Andhra Pradesh and the occupation of the new facility by food testing activities.

Strategic Entry into Biologics Contract Research and Development

Vimta Labs is expanding into biologics contract research and development services, with equipment procurement currently underway and commercialization targeted for Q1 FY27. This strategic move aims to offer an end-to-end service package, including characterization, analytical, preclinical, clinical, and formulation development, providing a unique competitive advantage in the market. Approximately INR30 crores of the planned FY26 capex is allocated to setting up these biologics services.

Electrical and Electronics Testing Outlook

The electrical and electronics testing services remained stable in Q1 FY26. Management views this as a 'sunrise industry' with significant growth potential, particularly driven by the defense and telecom sectors in the next 2-3 years. The company has already installed a second EMI/EMC chamber, indicating good utilization of existing capacities and readiness for future demand, especially as regulations continue to develop.

Capital Expenditure and Capacity Expansion Plans

For FY26, Vimta Labs plans a capex outlay of approximately INR100 crores. This follows an FY25 capex of upward of INR60 crores primarily for the new facility. The FY26 capex will be used for the biologics setup (INR30 crores), new/replacement equipment, and digitization initiatives. The new facility, which houses food testing and will accommodate preclinical activities, is expected to manage the company's growth for the next half a decade.

Margin Outlook and Shareholder Returns

While current EBITDA margins are strong at 35.7%, management anticipates a potential 1-2% reduction in the coming quarters. This expected compression is attributed to costs associated with new facility maintenance, lab redesigning, and increasing human resource expenses, before margins stabilize. In a move to enhance shareholder value, the Board approved a 1:1 bonus issue, reflecting confidence in the company's financial strength and future growth prospects.

Domestic vs. Export Market Dynamics

Management noted that while export revenues have grown proportionately to the overall business, domestic revenue has remained flat or slightly degrown. This trend is explained by the Indian market reaching a mature level, offering fewer growth opportunities compared to overseas markets. The company emphasizes its focus on addressing the high-quality requirements of developed markets, viewing the export growth as a positive rather than the domestic trend as a negative.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls